Search

AER001

AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

Oritavancin

[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

CRx-401

In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose … has proven to be well tolerated in clinical trials.

Triacetin

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

Cynodon dactylon pollen

It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

AN-9

Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. … greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in

Sermorelin

Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing

Dodecyldimethylamine N-oxide

Amniotic Epithelial Cells

[A220183,T823] These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.[A220183]